Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nonacog alfa

Drug Profile

Nonacog alfa

Alternative Names: BeneFIX; Blood-coagulation-factor-IX-synthetic-human; Coagulation Factor IX (Recombinant) - Pfizer; Factor IX - Wyeth; Factor-IX-Genetics-Institute; Recombinant Factor IX - Wyeth

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Oxford; Washington Research Foundation
  • Developer Grifols; Pfizer
  • Class Antihaemorrhagics; Blood coagulation factors
  • Mechanism of Action Blood coagulation factor replacements; Factor IX stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia B
  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemophilia B

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 28 Apr 2018 No recent reports of development identified for phase-I development in Haemophilia-B in China (IV, Infusion)
  • 05 Aug 2016 Takeda and Pfizer terminates its commercialisation agreement for nonacog alfa in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top